

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739

Date: 24 May 2024

To Corporate Relationship Department BSE Limited, 1st Floor, Rotunda Building, P.J. Towers, Dalal Street, Mumbai – 400 001. To National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) Mumbai – 400 051.

Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED

Dear Sir/Madam,

Sub: Revised Investor Presentation of the Company for the quarter & year ended 31 March 2024 **Ref:** Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, the Revised Investor Presentation for the quarter and year ended 31 March 2024, on Company Overview, Business highlights, financial performance and other updates is enclosed herewith for your consideration.

We request you to take the same on record.

Thanking you

For Shilpa Medicare Limited,

Ritu Tiwary Company Secretary & Compliance Officer

Shilpa Medicare Limited (SML)

Q4 & FY24 Investor Presentation

May 2024



Innovating for affordable healthcare

Table of content









Company Overview

Business Overview

API

Niche player in high potent oncology and select Non-oncology products

Investing in peptides & high-end polymers

Finished Dosage Form

Differentiated portfolio focusing on improved patient compliance

NDDS platforms of ODF & TDS

Biosimilars

Select high value low competition molecules

World class developmental & manufacturing capabilities

NBE - Recombinant Albumin

Synthetic product for significant global shortage plasma product

Manufacturing plant setup with large capacities

Integrated one stop CDMO solutions across segments based on strong R&D and manufacturing capabilities



Group Overview – Major Entities

Company Name	Product line	Plant location	Approvals
Shilpa Medicare (Parent listed entity)	a) Formulation - Onco & Adjuvent Oral & Inj b) Formulation – ODF & Transdermal + R&D center	a) Jadhchelra b) Bangalore	a) USFDA (under IA), EUGMP, ANVISA, TGA, Health Canada, COFEPRIS, DIGIMED-Peru, WHO GMP b) UK MHRA, UAE, WHO-GMP & DSIR approved
Shilpa Pharma Lifesciences (100%)	API – Onco & Non-onco, Peptides, Polymers, Intermediates	2 plants in Raichur	USFDA, EUGMP, PMDA, Cofepris, KFDA, WHO GMP
Shilpa Biologics (100%)	Biosimilars (MABs, Microbial & Vaccine manufacturing), CDMO/CMO	Dharwad	WHO-GMP & DSIR approved
Shilpa Biocare (100%)	Recombinant Albumin & fermentation facility	Kadechur	
Shilpa Therapeutics (100%)	Formulation - ODF	Hyderabad	WHO GMP, Kenya, Yemen, Malaysia
FTF Pharma (100%)	Formulation CRO	Ahmedabad	



R&D Competence

Multi location R&D teams to tap into right talent pool

- Raichur
- Ahmedabad
- Bengaluru
- Dharwad

Patents	Numbers*
API	213
Films and Topicals	37
Biologicals	14
Formulation	300
Total	564




- Multi disciplinary R&D team across APIs, Finished Dosage Formulation (including NDDS products) & Biological products
- Consists of highly qualified and well trained 35+ Doctorates, 30+ PhDs and 200+ MSc / M-Tech

- R&D well supported by IPM team for development and filing of patent applications
- Carefully crafted IP strategy for patent challenges and 505(b)(2) filings

*As on 31st March 2024



API - Overview



Finished Dosage - Overview

Carefully selected differentiated portfolio of Onco & Non-Onco products incl. 505(b)(2) opportunities

Focus on ease of administration & patient compliance

Venturing into NDDS platforms with ODFs & TDS product pipeline

Global supplier focusing on B2B model ensuring licensing, supplies & profit share revenues

Supplies to US, EU, India & Emerging markets

- establishing ground presence in US & strengthening Emerging markets team



Biosimilar - Overview

CAPABILITIES

- World class manufacturing & R&D facility at Dharwad Karnataka
- Handle mammalian, microbial & fermentation products
- End to end capability from clone development to upstream development to down stream developments
- Front end sales team established 4 products in the portfolio incl. own Adalimumab

PORTFOLIO

- Prudent portfolio selection focusing on limited competition differentiated products
- First product High concentration Adalimumab already launched in India under own brand & also partnered with Sun Pharma for Indian market – out licensed for certain emerging markets
- Aflibercept Phase III approval received from CDSCO Phase III expected to be initiated soon
- Additional products under development Abatacept, Etanercept & Pembrolizumab

CDMO

First CDMO project for microbial fermentation from a client for Korea Market









Business Updates

Managing Director's Message

Commenting on Q4 & FY'24 performance, Mr. Vishnukant Bhutada, Managing Director Shilpa Medicare Limited said

"I am pleased to inform you that our unwavering focus on building a sustainable and resilient business has allowed us to navigate the challenging period of the past couple of years with remarkable success. Our consistent quarter-over-quarter improvement in performance is a testament to our team's hard work and dedication, and a clear sign that our business is firmly back on a path of profitability and growth.

We recently achieved a significant milestone by raising equity funding of Rs. 500 crores through the QIP route, with participation from marquee investors. This substantial capital influx will not only significantly deleverage our balance sheet but also provide the essential growth funding to propel us further along our ambitious growth trajectory.

- Our Formulation business has reached new heights with the launch of our first NDA product, Pemetrexed RTU, under the J Code in the lucrative US market by our esteemed partner, Amneal. This landmark achievement underscores our commitment to innovation and our ability to deliver cutting-edge products to global markets. Additionally, we have strategically expanded our geographical reach by entering several emerging markets through our marketing partners, providing access to private markets and enabling us to participate in local tenders. This diversification will strengthen our position and drive sustainable growth.
- Our **Transdermal Portfolio** continues to gain traction, with the recent signing of licensing deals for two more products for the European Union markets. With a total of **three transdermal products now licensed out for the EU markets**, we are well-positioned to capitalize on this lucrative opportunity and deliver innovative solutions to patients worldwide.
- Following a successful inspection by AGES, Austria, our **Jadcherla facility has been issued a GMP Certification**, facilitating continued supplies to various countries of the European Union from this strategically important unit. This achievement attests to our commitment to quality and compliance.
- Our **CDMO business** is making significant strides on the signed projects, achieving various project milestones. This not only strengthens our relationships with existing clients and increases wallet share but also enables us to attract new clients and expand our client base.
- On the **Biological** front, we are **increasing our market share for our high-concentration Adalimumab** product in the Indian market. We have formed a strategic collaboration with one of the top Indian MNCs for the **commercialization of our second biological product, Aflibercept**, post approval.
- Our large-scale fermenting facility for the manufacture of **recombinant Albumin** is under construction, and we expect it to be **completed by the end of Q1 FY25**. We have already successfully completed phase 1 trials for this novel product, opening up potential licensing opportunities and positioning us at the forefront of innovation in this category.

Moving forward, I am confident that with our improved business mix, cost rationalization efforts, and balance sheet deleveraging, we are well-equipped to build a stronger, more niche-focused business that will deliver sustainable long-term growth and profitability. We are excited for the journey ahead and thankful for all our stakeholders' support."



API Update

Developments

Significant Commercial Update 2 molecules in the portfolio at validation stage which are expected to be completed in Q1 FY 25


- Methotrexate part of Oncology portfolio as an import substitute molecule
- 2 Liraglutide our 3rd peptide molecule trial batch successfully completed meeting global grade quality
- One Nutraceutical product for a customer validation completed in Q4 FY24
- Tranexamic Acid : capacity enhancement from 15 MT 25 MT expected to be completed by December 24

- Specialty polymer developed and clinical supplies done for US market, New polymer project initiated and planned to complete by Q2 FY 25
- Clinical supplies and commercialization for clients CDMO projects initiated



API - DMF Filings

New product introduction and increase in geographical coverage replicated with **244 DMF filings** done with major regulatory authorities






Formulation Update





Finished Dosage Form - Regulatory Filings

Robust regulatory filings to strength the base for growth in the formulation segment





ng 15

Biologics - Update



Adalimumab

High Concentration Adalimumab injection

- Increasing the volumes in the India market
- Executed Licensing and supply agreements for Emerging markets for Filling and supplies of the product in customer brand



Albumin

Recombinant Albumin

- Phase I initiated for the product and completed
- Phase I data shall be submitted to CDSCO for way forward for Phase III
- Product has been granted NBE(New Biological Entity) status
- Excipient grade DMF will be filed by Q1 FY25



Biologics Update

Aflibercept

- Phase III approval received from CDSCO and plans underway to initiate the clinical trial - a significant milestone in the development
 - Manufacturing of CT batches ongoing for phase III trial
 - Phase III initiation expected in Q2 FY 25 and completion likely by Q2 FY 26
- Moving ahead in advancing our commitment to delivering safe and effective solutions for various eye conditions

CDMO

 First CDMO project for microbial fermentation with Korean client has moved to second stage




 Second CDMO project signed with a US client



Additional Products Under Development

- Abatacept
- Etanercept
- Pembrolizumab
- Nivolumab









Performance Insights

Q4 FY24 Performance

Revenues INR 294.2 Cr	EBITDA	INR 72.6	5 Cr		
Revenue Break-up	Q4FY24 (Consolidated, INR Cr)				
Biologicals 4% 1%	Particulars	Q4 FY24	VS Q4 FY23	Vs Q3 FY24	
	Total Revenue	294.2	11%	2%	
Formulation 33%	EBITDA	72.6	80%	6%	
3376	EBITDA Margin	24.6%			
API	PAT	24.5			
62%		9.2%			




FY24 Financial Performance

Revenues INR 1,159.8 Cr	EBITDA	INR 252.7 Cr				
Revenue Break-up	FY24 (Consolidated, INR cr)					
Biologicals 3% 1%		Actuals	VS FY23			
Formulation	Total Revenue	1,159.8	9%			
30%	EBITDA	252.7	111%			
	EBITDA Margin	21.7%				
	PAT	32.0				
API 66%	PAT Margin	3%				



Consolidated Performance – Quarterly Trends









API Business Highlights Q4FY24

(INR in Cr.)




API Business Highlights FY24






Formulation Business Highlights Q4 FY24





Formulation Business Highlights FY24









Financial Performance

Balance Sheet - Consolidated

Particulars	31-Mar-24	31-Dec-23	31-Mar-23
Fixed Assets	1,384.9	1,359.8	1,368.3
Tangible Assets	1,193.2	1,162.4	1,179.4
Intangible Assets	191.7	197.5	188.9
Capital WIP	718.8	726.4	655.3
Tangible Assets	403.0	420.7	358.0
Intangible Assets	315.8	305.7	297.3
Other Non-current Assets	102.5	103.1	110.7
Net Working Capital	558.9	516.0	492.0
Current Assets	846.4	794.9	748.0
Cash and cash equivalents	30.4	21.7	21.6
Current Liabilities	-317.9	-300.7	-277.5
Total Assets (Net)	2,765.0	2,705.3	2,626.4
Equity	1,800.0	1,777.2	1,774.4
Borrowings (Current & Non current)	935.6	889.0	795.7
Other Non Current Liabilities	29.5	39.1	56.3
Total Liabilities	2,765.0	2,705.3	2,626.4



P&L - Consolidated

(INR in Cr.)

Particulars	Q4 FY24	Q4 FY23	% change	Q3 FY24	% change	FY24	FY23	% change
Revenues	294.2	265.7	11%	288.7	2%	1,159.8	1,067.5	9%
Gross Margin	197.1	176.3	12%	192.2	3%	752.2	651.1	16%
Gross Margin %	67%	66%	100 bps	67%	-	65%	61%	400 bps
Employee Cost	66.5	72.4	-8%	69.1	-4%	281.5	286.4	-2%
Other Expenses	58.1	63.5	-8%	55	6%	218.1	245	-11%
EBITDA	72.55	40.4	80%	68.2	6%	252.7	119.7	111%
EBITDA Margin	25%	15%	1000 bps	24%	100 bps	22%	11%	1100 bps
Finance Cost	24.2	17.7	36%	26.2	-8%	91.8	58.7	57%
Depreciation	26.6	25.7	4%	26.7	0%	107.9	95.5	13%
PBT	27.7	-3.7	-	14.2	95%	54.3	-38.3	-
PAT	24.5	-7.6	-	4.7	421%	32	-31	-
PAT Margin	8%	-		2%	600 bps	3%	-	



Balance Sheet – SML Standalone

Particulars	31-Mar-24	31-Dec-23	31-Mar-23
Fixed Assets	586.3	588.6	608.9
Tangible Assets	504.1	503.5	517.0
Intangible Assets	82.2	85.1	92.0
Capital WIP	228.2	235.5	226.4
Tangible Assets	9.9	24.3	41.8
Intangible Assets	218.3	211.2	184.6
Other Non-current Assets	1,227.1	1,206.3	1,047.0
Net Working Capital	276.9	254.3	553.1
Current Assets	373.8	331.4	631.4
Cash and cash equivalents	3.1	4.2	4.8
Current Liabilities	-100.0	-81.3	-83.1
Total Assets (Net)	2,318.5	2,284.1	2,435.5
Equity	2,142.7	2,134.6	2,117.6
Borrowings (Current & Non current)	142.5	115.5	287.4
Other Non Current Liabilities	33.3	34.0	30.6
Total Liabilities	2,318.5	2,284.1	2,435.5



P&L – SML Standalone

(INR in Cr.)

Particulars	Q4 FY24	Q4 FY23	% change	Q3 FY24	% change	FY24	FY23	% change
Revenues	110.7	74.6	48%	86.3	28%	398.9	316.3	26%
Gross Margin	78.2	61.3	28%	67.8	15%	309.7	234.1	32%
Gross Margin %	71%	82%	-1100 bps	79%	-800 bps	78%	74%	400 bps
Employee Cost	24.3	26.3	-8%	25.3	-4%	103.6	109.5	-5%
Other Expenses	23.7	28.5	-17%	23.5	1%	90.6	100	-9%
EBITDA	30.2	6.6	357%	19	59%	115.4	24.6	368%
EBITDA %	27%	9%	1800 bps	22%	500 bps	29%	8%	2100 bps
Finance Cost	2.7	6.5	-59%	2.6	4%	17.3	20.8	-17%
Depreciation	12.3	12	3%	12.4	-1%	49.6	46.5	7%
PBT*	11.4	-26.8	-	4	185%	38.1	-58.3	-
PAT	9.7	-28.9	-	2.7	259%	26.9	-49.5	-
PAT Margin	9%	-	-	3%	500 bps	7%	-	-



Thank You

Shilpa Medicare: Mr Dilip Kankani Contact: +91 8532 238704 Email: dilipkankani@vbshilpa.com **EY IR :** Mr Nachiket Kale Contact: +91 9920 940808 Email: <u>nachiket.kale@in.ey.com</u>